OM99-2
OM99-2 Basic information
- Product Name:
- OM99-2
- Synonyms:
-
- OM99-2
- H-GLU-VAL-ASN-[(2R,4S,5S)-5-AMINO-4-HYDROXY-2,7-DIMETHYL-OCTANOYL]-ALA-GLU-PHE-OH
- EVNL-PSI-AAEF
- GLU-VAL-ASN-(2R,4S,5S)-5-AMINO-*4-HYDROXY-2,7-DIMET
- [2-AMINOBENZOYL-GLY1]-GALANIN FRAGMENT (1-10)-LYS(RETRO-M-NITRO-TYR) AMIDE HUMAN
- [2-aminobenzoyl-gly1]-galanin fragment (1-10)-lys(retro-m-nitro-tyr) amide, human trifluoroacetate salt
- glu-val-asn-[(2r,4s,5s)-5-amino-4-hydroxy-2,7-dimethyloctanoyl]-ala-glu-phe
- OM99-2;[2-AMINOBENZOYL-GLY1]-GALANIN FRAGMENT (1-10)-LYS(RETRO-M-NITRO-TYR) AMIDE, HUMAN TRIFLUOROACETATE SALT
- CAS:
- 314266-76-7
- MF:
- C41H64N8O14
- MW:
- 892.99
- Product Categories:
-
- Galanin Degrading Zinc-MetallopeptidaseEnzyme Substrates
- Galanin degrading zinc-metallopeptidasePeptides for Cell Biology
- Enzyme Substrates
- Galanins
- Neuropeptides
- Protease Substrates
- Substrates by Enzyme
- Mol File:
- 314266-76-7.mol
OM99-2 Chemical Properties
- Boiling point:
- 1346.5±65.0 °C(Predicted)
- Density
- 1.289±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- form
- solid
- pka
- 3.48±0.10(Predicted)
Safety Information
- Safety Statements
- 22-24/25
- WGK Germany
- 3
OM99-2 Usage And Synthesis
Uses
OM99-2, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a Ki value of 9.58 nM[1]. OM99-2 is significantly advanced the development of BACE1 inhibitor[2]. OM99-2 has the potential for the research of the Alzheimer's disease[3].
Biological Activity
Cell permeable: no', 'Primary Target
human brain memapsin 2', 'Product does not compete with ATP.', 'Reversible: no', 'Target Ki: 1.6 nM against recombinant memapsin 2; 9.58 nM against recombinant pro-memapsin 2; 48 nM against cathepsin D
IC 50
BACE1
References
[1] Ghosh AK, et al. Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase). J Am Chem Soc. 2000;122(14):3522-3523. DOI:10.1021/ja000300g
[2] Zhao J, et al. Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. Front Mol Neurosci. 2020;13:137. Published 2020 Aug 4. DOI:10.3389/fnmol.2020.00137
[3] Dash C, et al. Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol. 2003;38(2):89-119. DOI:10.1080/713609213
[4] Park H, et al. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J Am Chem Soc. 2003;125(52):16416-16422. DOI:10.1021/ja0304493
OM99-2Supplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- info@creative-peptides.com